An emerging role for PtdIns(4,5)P2-mediated signalling in human disease.
Although an established regulator of many cellular functions, the phosphoinositide phosphatidylinositol (4,5)-bisphosphate [PtdIns(4,5)P2) appears to have evaded the attention of drug-discovery companies. An increasing number of reports have identified potential links between PtdIns(4,5)P2-mediated signalling pathways and the aetiology of many human diseases. Here, we review current knowledge of the regulation and function of PtdIns(4,5)P2 and discuss how aberrant PtdIns(4,5)P2-mediated signalling might contribute to human pathologies such as cardiac failure, bipolar disorder, channelopathies and the genetic disorder Lowe syndrome.
Halstead
Jonathan R
JR
Department of Cellular Biochemistry, the Netherlands Cancer Institute, AvL ziekenhuis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. j.halstead@nki.nl
Jalink
Kees
K
Divecha
Nullin
N
D000818:Animals; D001714:Bipolar Disorder / Q000378:metabolism*; D006331:Heart Diseases / Q000378:metabolism*; D006801:Humans; D007473:Ion Channels / Q000378:metabolism*; D009800:Oculocerebrorenal Syndrome / Q000378:metabolism*; D019269:Phosphatidylinositol 4,5-Diphosphate; D018129:Phosphatidylinositol Phosphates / Q000378:metabolism*; D015398:Signal Transduction
D007473:Ion Channels; D019269:Phosphatidylinositol 4,5-Diphosphate; D018129:Phosphatidylinositol Phosphates